亚克隆TP53拷贝数与多发性骨髓瘤预后相关
研究对1777例新诊断多发性骨髓瘤(MM)患者(Myeloma XI试验)用MLPA检测TP53拷贝数克隆异质性,发现亚克隆TP53缺失与总生存期缩短独立相关(HR 1.8,95%CI 1.2-2.8,P=.01);克隆性而非亚克隆性TP53缺失与晚期疾病标志物及基因组不稳定特征相关。
要点
- 亚克隆TP53缺失与MM患者总生存期缩短独立相关(HR 1.8,95%CI 1.2-2.8,P=.01)。
- 克隆性而非亚克隆性TP53缺失与晚期疾病标志物(血小板低、LDH高)及基因组不稳定特征相关。
- 双等位基因TP53功能缺失(突变+缺失)罕见(2.4%),与晚期疾病相关。
核心结论
- 亚克隆TP53缺失与多发性骨髓瘤患者总生存期缩短独立相关,克隆性而非亚克隆性TP53缺失与晚期疾病标志物相关。
研究设计与样本
- 研究纳入1777例新诊断多发性骨髓瘤患者(Myeloma XI试验),采用多重连接依赖探针扩增(MLPA)分析肿瘤样本的TP53拷贝数克隆异质性。
主要发现
- 亚克隆TP53缺失与更短的总生存期独立相关,风险比(HR)为1.8(95%置信区间1.2-2.8;P=.01)。
- 克隆性而非亚克隆性TP53缺失与晚期疾病的临床标志物相关,包括较低的血小板计数(P<.001)和升高的乳酸脱氢酶(P<.001)。
- 克隆性而非亚克隆性TP53缺失与提示基因组不稳定的特征频率更高相关,包括del(13q)(P=.002)或del(1p)(P=.006)。
- 双等位基因TP53功能缺失(由突变和缺失导致)罕见(2.4%),且与晚期疾病相关。
关键数值与推荐
- 研究提出通过MLPA识别亚克隆TP53缺失的框架,以改善多发性骨髓瘤患者分层和个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 newly diagnosed Myeloma XI trial patients with multiplex ligation-dependent probe amplification (MLPA). Subclonal TP53 deletions were independently associated with shorter overall survival, with a hazard ratio of 1.8 (95% confidence interval, 1.2-2.8; P = .01). Clonal, but not subclonal, TP53 deletions were associated with clinical markers of advanced disease, specifically lower platelet counts (P < .001) and increased lactate dehydrogenase (P < .001), as well as a higher frequency of features indicative of genomic instability, del(13q) (P = .002) or del(1p) (P = .006). Biallelic TP53 loss-of-function by mutation and deletion was rare (2.4%) and associated with advanced disease. We present a framework for identifying subclonal TP53 deletions by MLPA, to improve patient stratification in MM and tailor therapy, enabling management strategies.
引用
- Shah V, Johnson DC, Sherborne AL, et al. Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood. 2018. PMID: 30373884. doi:10.1182/blood-2018-06-857250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。